IRIS
CORTELLINI, ALESSIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.877
AS - Asia 1.319
EU - Europa 1.229
SA - Sud America 280
AF - Africa 29
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 5.740
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.818
SG - Singapore 754
IE - Irlanda 413
BR - Brasile 252
CN - Cina 207
DE - Germania 174
RU - Federazione Russa 157
HK - Hong Kong 137
IT - Italia 93
VN - Vietnam 92
UA - Ucraina 88
FI - Finlandia 67
SE - Svezia 50
GB - Regno Unito 46
CZ - Repubblica Ceca 42
CA - Canada 35
PL - Polonia 28
TR - Turchia 25
JP - Giappone 20
MX - Messico 18
BE - Belgio 16
IN - India 16
IQ - Iraq 14
ZA - Sudafrica 14
FR - Francia 11
BD - Bangladesh 10
ES - Italia 10
AR - Argentina 7
ID - Indonesia 7
NL - Olanda 7
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
EC - Ecuador 5
CO - Colombia 4
IL - Israele 4
JO - Giordania 4
UZ - Uzbekistan 4
AL - Albania 3
AT - Austria 3
AZ - Azerbaigian 3
EE - Estonia 3
EG - Egitto 3
EU - Europa 3
KE - Kenya 3
LT - Lituania 3
MA - Marocco 3
PT - Portogallo 3
VE - Venezuela 3
BG - Bulgaria 2
CH - Svizzera 2
HN - Honduras 2
KR - Corea 2
NZ - Nuova Zelanda 2
PH - Filippine 2
PK - Pakistan 2
RO - Romania 2
RS - Serbia 2
SA - Arabia Saudita 2
TN - Tunisia 2
AU - Australia 1
BN - Brunei Darussalam 1
CG - Congo 1
CI - Costa d'Avorio 1
CL - Cile 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
GH - Ghana 1
GY - Guiana 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
LU - Lussemburgo 1
MC - Monaco 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
MY - Malesia 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
Totale 5.740
Salva come PNG Salva come JPEG
Città #
Dallas 517
Chandler 430
Dublin 413
Singapore 383
Jacksonville 305
Ashburn 218
Santa Clara 142
Hong Kong 137
Boardman 123
New York 99
Munich 77
Ann Arbor 61
Princeton 58
Beijing 57
Lawrence 57
Los Angeles 52
Helsinki 47
The Dalles 46
Wilmington 43
Brno 42
Ho Chi Minh City 33
Columbus 26
Moscow 26
São Paulo 26
Warsaw 26
Bremen 21
Tokyo 20
Dong Ket 18
Montreal 18
Dearborn 17
Assago 16
Brussels 16
Stockholm 16
Brooklyn 15
Denver 14
Falkenstein 14
Chicago 13
L'aquila 13
San Francisco 13
Johannesburg 12
Turku 12
Atlanta 11
Hanoi 11
Frankfurt am Main 10
Izmir 10
London 10
Nanjing 10
Belo Horizonte 9
Milan 9
San Jose 9
Brasília 8
Orem 8
Phoenix 8
Rio de Janeiro 8
Seattle 8
Boston 7
Mexico City 7
Poplar 7
Amsterdam 6
Guangzhou 6
Houston 6
Lappeenranta 6
Nanchang 6
Pune 6
Ankara 5
Berlin 5
Haiphong 5
Hefei 5
Jinan 5
L’Aquila 5
Norwalk 5
San Mateo 5
Tianjin 5
Toronto 5
Amman 4
Asunción 4
Baghdad 4
Bauru 4
Cagliari 4
Campinas 4
Chennai 4
Council Bluffs 4
Da Nang 4
Jakarta 4
Juneau 4
Manchester 4
New Delhi 4
Oklahoma City 4
Querétaro 4
Redwood City 4
Shanghai 4
Woodbridge 4
Baku 3
Charlotte 3
Curitiba 3
Des Moines 3
Dhaka 3
Erbil 3
Guayaquil 3
Hải Dương 3
Totale 4.024
Salva come PNG Salva come JPEG
Nome #
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 154
"Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer 132
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 124
Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases 124
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 124
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 123
Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series 120
Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer 119
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 117
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice 116
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice 113
Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy 113
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 112
A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? 112
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 110
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice 109
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 108
Evaluation of prognostic factors for survival in transverse colon cancer 105
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 103
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. 102
Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab 102
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome 102
The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings 102
A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients 100
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 99
Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study 99
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 98
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience 97
Timed-flat infusion (TFI) 5-fluorouracil with irinotecan and oxaliplatin in pancreatic adenocarcinomas: A single institution experience with FIr/FOx regimen 97
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 96
A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy 96
The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study 95
The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference 95
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 94
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study 94
Looking for a place for dose-dense TMZ regimens in GBM patients: An experience with MGMT exploratory evaluation 94
Cancer care after natural disaster: Different countries, similar problems 93
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 91
Topical menthol for treatment of chemotherapy-induced peripheral neuropathy 91
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 90
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 90
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey 87
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 86
Rare bone toxicity associated with vismodegib 86
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 85
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 85
Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience 85
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 83
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma 81
The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients 79
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis 75
Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen 74
Studio sul ruolo della storia familiare di neoplasie come fattore predittivo surrogato per l'immunoterapia con inibitori dei checkpoint immunitari PD-1/PD-L1 70
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 65
Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report 64
"palliative" or "supportive": Is It Just a Matter of Word? 62
Family history of cancer and DNA damage response genes: Two sides of the same coin? 60
Practical Advices About How To Handle Disease Progression During Osimertinib In EGFR-Mutant NSCLC Patients: Is It The Same Old Story? A Mini Review 60
Retrospective evaluation of chemotherapy options in non-squamous non-small cell lung cancer (non-Sq NSCLC) patients (pts) unfit for standard platinum-based chemotherapy in clinical practice 52
Prognostic relevance of Hormonal Receptor positive Status in HER2-positive Metastatic Breast Cancer Patients: Retrospective Analysis in Real Life 52
First-line chemotherapy with docetaxel, oxaliplatin, and timed-flat infusion 5Fluorouracil in metastatic gastro-esophageal adenocarcinomas: The experience with FD/FOx regimen 50
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study 45
Totale 5.841
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.554
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021237 0 0 0 0 0 8 58 9 75 6 60 21
2021/2022209 4 1 16 8 11 4 3 19 23 2 23 95
2022/20231.193 65 95 9 148 88 114 2 89 516 6 43 18
2023/2024389 38 7 17 20 29 110 3 49 0 17 19 80
2024/20251.515 46 28 119 101 145 110 221 100 369 50 138 88
2025/20261.756 157 300 393 374 349 183 0 0 0 0 0 0
Totale 5.841